

FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D



2/32

FIG. 1E





FIG. 1F



3/32

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D





FIG. 2E



4/32

FIG. 2F






FIG. 2G





6/32

FIG. 3D

*HPRT probe	Sequence
HPRT primer set	5'-/56-FAM/TCCAAAGAT/ZEN/GGTCAAGGTCGCAAG/3IABkFQ/-3'
	5'-ACTTCGTGGGGTCCTTTTC-3'
	5'-CTTTGCTTTCCTTGGTCAGG-3'
*MUC5AC probe	Sequence
MUC5AC primer set	5'-/56-FAM/CGTTTGACG/ZEN/GGAAGCAATACACGG/3IABkFQ/-3'
	5'-TACCTGCTCTGTGCTTGGAG-3'
	5'-AGGGCTTGGTCAGCACATA-3'
*MUC5B probe	Sequence
MUC5B primer set	5'-/56-FAM/AACCCCGTA/ZEN/GAAGGTGCCATTGT/3IABkFQ/-3'
	5'-CCAGAGAGGCAGGTACACAT-3'
	5'-GCAGACCTCAGCTGTGTT-3'

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D





FIG. 4E



8/32

FIG. 4F





FIG. 4G



Experimental Group	Drug
Group A - Saline/Saline	Vehicle
Group B - Saline/Saline	Jag1 (80mpk)
Group C - Saline/Saline	Isotype Control (80 mpk)
Group D - OVA/OVA	Vehicle
Group E - OVA/OVA	Jag1
Group F - OVA/OVA	Isotype Control
Group G - OVA/OVA	aTSLP (20mpk)

9/32

FIG. 5A

Immunization (IP) on day 0 & 14

Ab administration (IV) on day 0, 7, 14 & 20

OVA challenge (IH) on day 21, 23, 24 & 26






FIG. 5B




10/32

FIG. 5C



11/32

FIG. 6



12/32

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10




FIG. 11






FIG. 12



16/32

FIG. 13



17/32

FIG. 14A




FIG. 14B





FIG. 14C



18/32

FIG. 14D

NRARP Normal Healthy Donor #448751




FIG. 14E

SCGB1A1 CF Donor #KK030G





FIG. 14F

MUC5AC CF Donor #KK030G



19/32

FIG. 14G

DNAI2 CF Donor #KK030G




FIG. 14H

NRARP CF Donor #KK030G





FIG. 14I

SCGB1A1 COPD Donor #OF3207



20/32

FIG. 14J

MUC5AC COPD Donor #OF3207




FIG. 14K

DNAI2 COPD Donor #OF3207





FIG. 14L

NRARP COPD Donor #OF3207



21/32

FIG. 15A




FIG. 15B





FIG. 15C



22/32

FIG. 15D

NRARP Normal Healthy Donor #448751




FIG. 15E

SCGB1A1 CF Donor #KK030G





FIG. 15F

MUC5AC CF Donor #KK030G



23/32

FIG. 15G

DNAI2 CF Donor #KK030G




FIG. 15H

NRARP CF Donor #KK030G





FIG. 15I

SCGB1A1 COPD Donor #OF3207



24/32

FIG. 15J

MUC5AC COPD Donor #OF3207




FIG. 15K

DNAI2 COPD Donor #OF3207





FIG. 15L

NRARP COPD Donor #OF3207



25/32

FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17A





FIG. 17B



27/32

FIG. 17C





FIG. 17D



28/32
FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D





FIG. 18E






FIG. 19B




FIG. 19C




FIG. 20A

Nasopharynx




FIG. 20B

Trachea




FIG. 20C

Bronchus




FIG. 20D

Nasopharynx




FIG. 20E

Trachea





FIG. 20F

Bronchus



32/32

FIG. 21A




FIG. 21B

